Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Standard
Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. / Abou Dalle, Iman; Labopin, Myriam; Kröger, Nicolaus; Schroeder, Thomas; Finke, Jürgen; Stelljes, Matthias; Neubauer, Andreas; Blaise, Didier; Yakoub-Agha, Ibrahim; Salmenniemi, Urpu; Forcade, Edouard; Itäla-Remes, Maija; Dreger, Peter; Bug, Gesine; Passweg, Jakob; Heuser, Michael; Choi, Goda; Brissot, Eolia; Giebel, Sebastian; Nagler, Arnon; Ciceri, Fabio; Bazarbachi, Ali; Mohty, Mohamad.
in: BONE MARROW TRANSPL, Jahrgang 58, Nr. 7, 07.2023, S. 784-790.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
AU - Abou Dalle, Iman
AU - Labopin, Myriam
AU - Kröger, Nicolaus
AU - Schroeder, Thomas
AU - Finke, Jürgen
AU - Stelljes, Matthias
AU - Neubauer, Andreas
AU - Blaise, Didier
AU - Yakoub-Agha, Ibrahim
AU - Salmenniemi, Urpu
AU - Forcade, Edouard
AU - Itäla-Remes, Maija
AU - Dreger, Peter
AU - Bug, Gesine
AU - Passweg, Jakob
AU - Heuser, Michael
AU - Choi, Goda
AU - Brissot, Eolia
AU - Giebel, Sebastian
AU - Nagler, Arnon
AU - Ciceri, Fabio
AU - Bazarbachi, Ali
AU - Mohty, Mohamad
N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2023/7
Y1 - 2023/7
N2 - Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). We aimed at evaluating the impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1). We identified a total of 3202 adult AML patients, of these 1776 patients were in CR1 and MRD positive and 1426 patients were primary refractory at time of transplant. After a median follow-up of 24.4 months, non-relapse mortality and relapse rate were significantly higher in the primary refractory group compared to the CR1 MRD positive group (Hazards Ratio (HR) = 1.82 (95% CI: 1.47-2.24) p < 0.001 and HR = 1.54 (95% CI: 1.34-1.77), p < 0.001), respectively. Leukemia-free survival (LFS) and overall survival (OS) were significantly worse in the primary refractory group (HR = 1.61 (95% CI: 1.44-1.81), p < 0.001 and HR = 1.71 (95% CI: 1.51-1.94), p < 0.001, respectively). Our real-life data suggest that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT with a 2-year OS of 63%, if negative MRD cannot be obtained and their outcomes are significantly better than patients transplanted with active disease.
AB - Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). We aimed at evaluating the impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1). We identified a total of 3202 adult AML patients, of these 1776 patients were in CR1 and MRD positive and 1426 patients were primary refractory at time of transplant. After a median follow-up of 24.4 months, non-relapse mortality and relapse rate were significantly higher in the primary refractory group compared to the CR1 MRD positive group (Hazards Ratio (HR) = 1.82 (95% CI: 1.47-2.24) p < 0.001 and HR = 1.54 (95% CI: 1.34-1.77), p < 0.001), respectively. Leukemia-free survival (LFS) and overall survival (OS) were significantly worse in the primary refractory group (HR = 1.61 (95% CI: 1.44-1.81), p < 0.001 and HR = 1.71 (95% CI: 1.51-1.94), p < 0.001, respectively). Our real-life data suggest that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT with a 2-year OS of 63%, if negative MRD cannot be obtained and their outcomes are significantly better than patients transplanted with active disease.
KW - Adult
KW - Humans
KW - Bone Marrow
KW - Transplantation, Homologous
KW - Hematopoietic Stem Cell Transplantation/adverse effects
KW - Leukemia, Myeloid, Acute
KW - Recurrence
KW - Neoplasm, Residual
KW - Cost of Illness
KW - Retrospective Studies
U2 - 10.1038/s41409-023-01961-1
DO - 10.1038/s41409-023-01961-1
M3 - SCORING: Journal article
C2 - 37041215
VL - 58
SP - 784
EP - 790
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 7
ER -